Dexcom’s CEO, Kevin Sayer, ahead of this year’s Advanced Technologies & Treatments for Diabetes conference, shared an update on the company’s recent news, future strategy and where he feels the market is headed.
On 5 March, Dexcom announced the US Food and Drug Administration had granted clearance to its Stelo blood glucose monitor, the first of its kind that will be sold over the counter.
Now, American type II diabetes patients who are not on insulin therapy will be able to easily access top-spec CGM...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
